Global Newsroom | CSL
WEBHead-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL... Read more news from CSL
News Releases - CSL
WEB4 days ago · Recent News Releases. For investor-related news, see our ASX releases here. Basic Search. Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...
News Releases - CSL
WEBApr 17, 2024 · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
News Releases | CSL
WEBPart of a A$2 billion infrastructure investment program in Australia undertaken by CSL over the past four years, the facility will house more than 850 professionals dedicated to protecting public health and bringing life-saving innovative therapies to those in need.
News Releases | CSL
WEBStudy results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year. Garadacimab underscores CSL's promise to develop innovative medicines for people living with rare diseases like HAE, a community CSL has been serving for 40 years.
Celebrating CSL's New Research and Development Center in …
WEBFor three years, anticipation has been building for the completion of CSL’s new R&D site in Marburg, Germany. On Tuesday, the doors opened for a launch event that showcased the state-of-the-art space, which will be powered by 500 R&D employees.
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial ...
WEBFeb 11, 2024 · Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human])...
News Releases - CSL
WEBMay 30, 2024 · CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season. CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a... May 21, 2023.
News Releases | CSL
WEBCSL Seqirus’ $800m+ innovative vaccine and antivenom manufacturing facility in Australia reaches major construction milestone. Melbourne, Monday 22 May. CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’.
Japan's Ministry of Health, Labor and Welfare Approves CSL and …
WEBSep 13, 2024 · Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma. Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and ...